User:Mr. Ibrahem/Taliglucerase alfa

Taliglucerase alfa, sold under the brand name Elelyso among others, is a medication used to treat Gaucher's disease type I. It is given by gradual injection into a vein. It is used long term.

Common side effects include headache, joint pain, tiredness, nausea, itchiness, and rash. Other side effects may include anaphylaxis. It is a glucocerebrosidase made by recombinant DNA technology and works by replacing this missing enzyme.

Taliglucerase alfa was approved for medical use in the United States in 2012. In Europe it received an orphan designation in 2010 but was declined approval in 2012 due to the similar product velaglucerase alfa having market exclusivity. In the United States it costs about 18,000 USD per dose for a 70 kg person (465,000 USD per year). It is the first plant-made medication to be approved in the United States.